United Therapeutics Corp

United Therapeutics Corp, a biotechnology manufacturer specializing in rare disease treatments, operates as a prime contractor supplying specialized pharmaceuticals exclusively to the Department of Veterans Affairs through GSA Federal Supply Schedule contracts and a single-award blanket purchase agreement. The company is self-certified as a small disadvantaged business and competes on a full-and-open basis without set-aside designation; it holds no subcontract footprint in the federal space.

United Therapeutics manufactures four branded pharmaceutical products for the VA: Tyvaso (treprostinil) inhalation solution in multiple formulations and dosages, Remodulin (subcutaneous injection), Orenitram (oral tablets), and Unituxin (chemotherapy agent). These medications treat pulmonary arterial hypertension and select oncology conditions affecting the veteran population. Representative work includes hundreds of small delivery orders under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) — for example, a $33,158.10 delivery order from VISN 5 on July 29, 2026 for Tyvaso DPI 80 mcg, and a $108,434.77 delivery order from VISN 20 on October 20, 2025 for Tyvaso kits and cartridges. Manufacturing is performed in Bartlett, Tennessee, with corporate operations in Silver Spring, Maryland.

Customer concentration is extreme and vertical. The Department of Veterans Affairs accounts for approximately 99 percent of combined potential value across all awards. Within the VA, Veterans Integrated Service Network 12 anchors the dollar concentration with $1.12 billion combined potential value across 20 awards — a bulk-order vehicle structure that dwarfs all other customers. The next tier includes the VA National Acquisition Center ($317.1 million across 4 awards), VISN 21 ($4.1 million across 123 awards), VISN 5 ($3.8 million across 258 awards), and VISN 20 ($2.8 million across 50 awards). The top five customers by potential value represent 99 percent of the portfolio. This concentration reflects United Therapeutics' role as the VA's exclusive supplier under a single-award indefinite delivery structure rather than competition for market share.

The primary vehicle is the $207.1 million single-award Blanket Purchase Agreement with the VA National Acquisition Center (awarded April 24, 2025, ceiling April 23, 2027), which operates under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). This BPA enables VISNs nationwide to issue delivery orders directly to United Therapeutics for its four pharmaceutical products at pre-negotiated firm fixed prices without competition. The underlying GSA Schedule (FSS-61-IB) itself carries 645 task orders totaling $337.4 million, representing the majority of recent activity. Secondary vehicles include Federal Supply Schedule vehicles designated V797P5096B (288 task orders, $17.6 million) and V797P5628X (48 task orders, $458 thousand), and a BPA designated V797P5096B-VA797BP0424 (38 task orders, $2.4 million). All vehicles are single-award, non-competitive instruments reflecting United Therapeutics' sole-source status for these specialized pharmaceuticals within the VA system.

Activity has remained relatively stable over the past five years, with 54 awards in 2022, 62 in 2023, 66 in 2024, 46 in 2025, and 52 through mid-2026. The portfolio comprises 952 prime awards with zero subcontract footprint. Combined potential value across all awards is $1.46 billion; combined dollars obligated represent only 2 percent of potential value, reflecting the indefinite delivery structure in which ceiling values are stated but actual spend tracks to veteran utilization. Primary NAICS classification is Pharmaceutical Preparation Manufacturing (944 of 952 awards); PSC concentration sits in Drugs and Biologicals (884 awards). No recompete cliff is evident within the next twenty-four months; the primary BPA expires April 23, 2027.

United Therapeutics holds a named subsidiary, Revivicor, Inc., a for-profit organization, though the source does not detail Revivicor's role in federal contracting or its relationship to the parent's VA pharmaceutical supply mission. The company's federal footprint is deliberately narrow — nearly 100 percent of awards flow through the VA healthcare system, and almost all work falls under two vehicle types: the GSA Pharmaceuticals and Drugs Schedule and the VA National Acquisition Center BPA. This concentration reflects a regulatory and market-access strategy centered on rare disease therapy rather than broad federal competition.